Keros Therapeutics (KROS) PT Slashed to $15 at Piper Sandler Following Trial Termination
Tweet Send to a Friend
Piper Sandler analyst Joseph Catanzaro slashes the price target on Keros Therapeutics (NASDAQ: KROS) to $15.00 (from $40.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
